SlideShare una empresa de Scribd logo
1 de 84
Descargar para leer sin conexión
Origins of Pain in the Head
• Extra-cranial pain
sensitive structures:
–
–
–
–
–
–
–

Sinuses
Eyes/orbits
Ears
Teeth
TMJ
Blood vessels
5,7,9,10 cranial nerves
carry pain from thes
strucure

• Intra-cranial pain
sensitive structures:
– Arteries of circle of willis
and proximal dural
arteries,
– Dural Venous
sinuses,veins
– Meninges
– Dura
Classification of Headaches
• PRIMARY - NO structural
or metabolic abnormality:
– Tension
– Migraine
– Cluster

• SECONDARY – structural
or metabolic abnormality:
– Extracranial: sinusitis, otitis
media, glaucoma, TMJ ds
– Inracranial:
SAH, vasculitis, dissection, ce
ntral vein
thrombosis, tumor, abscess,
meningitis
– Metabolic disorders: CO2
retention, CO poisoing
RED Flags
•
•
•
•
•
•
•
•

New onset headache in a patient >50 y.o.
Sudden, worst headache of one’s life
Morning headache associated with N/V
Fever, weight loss
Worsens with valsalva maneuvers
Focal neurologic deficits, jaw claudication
Altered LOC
Hx of trauma, cancer or HIV
Part 1:
The primary headaches
1. Migraine
2. Tension-type headache
3. Cluster headache
and other trigeminal autonomic cephalalgias
4. Other primary headaches

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
Primary Headache Types
Migraine

Tension

Pain
Throbbing, mod Pressure, t
Description
erate to
ightness,
severe, worse waxes and
w/exertion
wanes
Associated
Photo/phonoSymptoms phobia, n/v, aura

Bajwa and Wootton. Up to Date 2007

None

Cluster
Abrupt onset,
deep,
continuous,
excruciating,
explosive
Tearing,
congestion,
rhinorrhea,
pallor, sweating
Primary Headache Types
Migraine
Location
Duration
Patient
Appearance

Tension

Cluster

60-70%
unilateral
4-72 hr

Bilateral

Unilateral

0.5-3 hr,
many per day
Resting in Remains
Remains
quiet dark
active or active, prefers
room; young prefers to hot shower,
female
rest
male, smoker

Bajwa and Wootton. Up to Date 2007

Variable
1. Migraine
1.1 Migraine without aura
1.2 Migraine with aura
1.3 Childhood periodic syndromes that are
commonly precursors of migraine
1.4 Retinal migraine
1.5 Complications of migraine
1.6 Probable migraine

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
Pathophysiology
• Brainstem neuronal hyperexcitability
• Cortical spreading depression w/aura
• Abnormalities of 5-HT, CGRP, NE, DA, GABA,
glutamate, NO, and endorphins
• Trigeminal Activation

Marcus, DA. Headache Simplified 2008.
Presymptomatic hyperexcitabilty increases brain stem response to triggers

Release of Neurotransmitters
(5-HT, NE, DA, GABA, Glutamate, NO, CGRP, Substance P, Estrogen)

Neurotransmitters activate the Trigeminal Nucleus

Dilation of
Meningeal blood
vessels
(Throbbing)

Activation of
Area Postrema
(N/V)

Activation of
Hypothalamus
(Hypersensitivity)

Activation of
Cortex and
Thalamus (Head
pain)
Marcus, DA. Headache Simplified 2008.

Activation of
cervical trigeminal
system (Muscle
spasm)
1.1 Migraine without aura
A. At least 5 attacks fulfilling criteria B-D
B. Headache attacks lasting 4-72 h (untreated or
unsuccessfully treated)
C. Headache has 2 of the following characteristics:
1. unilateral location
2. pulsating quality
3. moderate or severe pain intensity
4. aggravation by or causing avoidance of routine
physical activity (eg, walking, climbing stairs)
D. During headache 1 of the following:
1. nausea and/or vomiting
2. photophobia and phonophobia
E. Not attributed to another disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.1 Migraine without aura
Notes

• If <5 attacks but criteria B-E otherwise met, code as
1.6.1 Probable migraine without aura
• When attacks occur on 15 d/mo for >3 mo, code as
Notes
1.1 Migraine without aura + 1.5.1 Chronic migraine
• Pulsating means varying with the heartbeat
• In children:
– attacks may last 1-72 h
– occipital headache requires caution
• In young children:
– photophobia and/or phonophobia may be inferred
from their behaviour

1.1 Migraine without aura

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
‘Not attributed to another
disorder’
Note

For all primary headaches, this criterion means:
• History and physical/neurological examinations do
not suggest any of the disorders listed in groups 5-12,
or history and/or physical/ neurological
examinations do suggest such disorder but it is ruled
out by appropriate investigations,
or such disorder is present but headache does not
occur for the first time in close temporal relation to
the disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2 Migraine with aura
1.2.1
1.2.2
1.2.3
1.2.4
1.2.5
1.2.6

Typical aura with migraine headache
1.2 aura with non-migraine headache
TypicalMigraine with aura
Typical aura without headache
Familial hemiplegic migraine (FHM)
Sporadic hemiplegic migraine
Basilar-type migraine

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2 Migraine with aura

A. At least 2 attacks fulfilling criterion B

1.2 Migraine with aura

B. Migraine aura fulfilling criteria B and C for one of the
subforms 1.2.1-1.2.6
C. Not attributed to another disorder

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2 Migraine with aura

Subtypes new to classification
1.2.1 Typical aura with migraine headache
•

1.2 Migraine with with headache
aura
most migraine auras are associated
Subtypes new to classification
fulfilling criteria for 1.1 Migraine without aura

1.2.2 Typical aura with non-migraine headache
1.2.3 Typical aura without headache
• migraine aura is sometimes associated with a
headache that does not fulfil these criteria
• or occurs without headache
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2.1 Typical aura
with migraine headache
A. At least 2 attacks fulfilling criteria B–D
B. Aura consisting of 1 of the following, but no motor
weakness:
1. fully reversible visual symptoms including positive
and/or negative features
2. fully reversible sensory symptoms including
positive and/or negative features
3. fully reversible dysphasic speech disturbance

1.2.1 Typical aura
with migraine headache

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2.1 Typical aura
with migraine headache
C. At least two of the following:
1. homonymous visual symptoms and/or unilateral
sensory symptoms
2. at least one aura symptom develops gradually over
5 min and/or different aura symptoms occur in
succession over 5 min
3. each symptom lasts 5 and 60 min
D. Headache fulfilling criteria B-D for 1.1 Migraine
without aura begins during the aura or follows aura
within 60 min
E. Not attributed to another disorder

1.2.1 Typical aura
with migraine headache

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2.2 Typical aura
with non-migraine headache
As 1.2.1 except:
D. Headache that does not fulfil criteria B-D for
1.1 Migraine without aura begins during the aura or
follows aura within 60 min

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2.3 Typical aura
without headache

1.2.3 Typical aura
without headache

As 1.2.1 except:
D. Headache does not occur during aura nor follow aura
within 60 min

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2.4 Familial hemiplegic
migraine (FHM)
A. At least 2 attacks fulfilling criteria B and C
B. Aura consisting of fully reversible motor weakness
and 1 of:
1. fully reversible visual symptoms including positive
and/or negative features
2. fully reversible sensory symptoms including
positive and/or negative features
3. fully reversible dysphasic speech disturbance

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.2.6 Basilar-type migraine
As 1.2.1 except:
B. Aura consisting of 2 of the following fully reversible
symptoms, but no motor weakness:
1. dysarthria; 2. vertigo; 3. tinnitus; 4. hypacusia;
5. diplopia; 6. visual symptoms simultaneously in both
temporal and nasal fields of both eyes; 7. ataxia;
8. decreased level of consciousness;
9. simultaneously bilateral paraesthesias

C. At least one of the following:
1. at least one one aura symptom develops gradually over
5 min and/or different aura symptoms occur in
succession over 5 min
2. each aura symptom lasts 5 and 60 min
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.3 Childhood periodic syndromes
that are commonly
precursors of migraine
1.3.1 Cyclical vomiting
1.3.2 Abdominal migraine
1.3.3 Benign paroxysmal vertigo of childhood

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
1.3.2 Abdominal migraine
A. At least 5 attacks fulfilling criteria B-D
B. Attacks of abdominal pain lasting 1-72 h
C. Abdominal pain has all of the following
characteristics:
1. midline location, periumbilical or poorly localised
2. dull or “just sore” quality
3. moderate or severe intensity
D. During abdominal pain 2 of the following:
1. anorexia; 2. nausea; 3. vomiting; 4. pallor
E. Not attributed to another disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
Types of Migraine Treatment
• Acute
– Taken during an attack
– Reduces pain, associated symptoms and disability
and stops progression

• Preventive
– Taken daily for months to years
– Reduces frequency, severity, and duration
– Used in addition to acute treatments
.
Acute Treatment Principles
• Treat attacks rapidly and consistently
• Tailor treatment to the patient and the sx

• Minimize adverse events and cost
• Limit to 3 days per week or less
Antiemetics
• Prevent and treat nausea
• Improve GI motility
• Enhance absorption of other anti-migraine
medications
• Limited RCT to support their use in migraine
Phenothiazines
• Promethazine (Phenergan)
– Available PO, IM, PR
– Dose = 25-50 mg Q6H PRN
– Blocks dopamine and histamine receptors

• Prochlorperazine (Compazine)
– Available PO, IM, IV, PR
– Dose = 5-10 mg Q6H PRN
– Blocks dopamine receptors

• SE = sedation, dizziness, dystonic rxn
Migraine Specific Medications
Triptans
Ergots
Acute Treatment - Triptans
Fast onset/short duration
• Sumatriptan
• Rizatriptan
• Zomitriptan
• Almotriptan
• Eletriptan
• Treximet (Suma +
Naproxen)

Slow onset/long duration
• Naratriptan
• Frovatriptan
Acute Treatment - Triptans
• Reasonable first choice for patients with moderate to
severe disability from migraines
• Limit use to 2-3 days per week
• Patients who fail one triptan often respond to
another
• Do not use one triptan within 24 hours of another
Acute Treatment - Triptans
Mechanism of action
• 5HT-1B/1D agonists
• Inhibit release of CGRP &
substance P
• Inhibit activation of the
trigeminal nerve
• Inhibit vasodilation in
the meninges

Johnston et al Drugs 2010
Loder NEJM 2010

Precautions
• Ischemic heart dz or
stroke
• High risk for CAD
• Pregnancy
• Hemiplegic or basilar
migraine
• Ergots
• Use w/ SSRIs?
Triptan Side Effects
•
•
•
•
•
•
•

Flushing, feeling or warmth
Chest pressure or heaviness
Throat tightness
Paresthesias
Dizziness, fatigue, drowsiness
Nausea
Intolerable taste with nasal formulations

Johnston et al Drugs 2010
Loder NEJM 2010
Triptan Comparison
Drug

Tmax (h)

T1/2 (h)

Metabolism

Sumatriptan 50 &100 mg
tablets

2.5

2

MAO-A

Sumatriptan 20 mg nasal

1

2

Sumatriptan 6 mg subQ

0.16-0.2

2

Zolmitriptan 2.5 mg tab

2

3

Zolmitriptan 2.5 mg ODT

3.3

2.5-3

Zolmitriptan 5 mg nasal

4

2.82

Rizatriptan 10 mg tab

1.2

2

Rizatriptan 10 mg ODT

1.6-2.5

2

Naratriptan

2-3

5-6

P450, 50% unchanged

Almotriptan

1.4-3.8

3.2-3.7

MAO-A, 3A4, and 2D6

Frovatriptan

2-4

26

Mostly unchanged

Eletriptan

1-2

3.6-5.5

3A4

2D6 and MAO-A

MAO-A
Acute Treatment – Ergots
• Mechanism of Action
– Constrict peripheral and cranial blood vessels
– Bind to 5HT, NE, DA, alpha and beta receptors

• Contraindications and precautions
– CAD or CVD (or high risk), uncontrolled HTN
– Hemiplegic or basilar migraine
– Pregnancy (category X) and breast feeding
– Drugs metabolized by CYP3A4, triptans
Ergot Side Effects
• Nausea and vomiting (pre-treat with antiemetic)
• Coronary artery spasm, angina, MI
• Tingling, numbness, Dizziness
• Increased BP and HR
• “Ergotism”
Choosing Acute Rx
Early N/V

Recurrence

• Nasal triptans
• Sumatriptan SubQ
• ODT triptans?

• Nara, Frova, Almotriptan
• Ergots
• Triptan + NSAID

Sensitive to SE

Rapid Onset

• Naratriptan
• Frovatriptan
• Almotriptan

• Sumatriptan SubQ
• Nasal Triptans
• DHE nasal or IM
Indications for a Preventive Agent
• Migraine-related disability > 3d/month

• Migraines last over 48 hours
• Acute treatments are contraindicated, ineffective, or
overused
• Migraines cause profound disability or prolonged aura
• Patient preference
Beta Blockers
• FDA approved for migraine prevention
– Propranolol (Inderal) 60-240 mg PO once daily for ER or divided
BID or TID for IR
– Timolol (Blocadren) 10-30 mg PO daily in 2 divided doses

• Limited evidence for migraine prevention
– Nadolol (Corgard) 20-240 mg PO once daily
– Atenolol (Tenormin) 50-150 mg PO daily or divided BID
– Metoprolol (Lotensin, Toprol XL) 100-200 mg daily or divided
BID for IR formulation
Beta Blockers
Advantages
• Thoroughly studied and
widely used
• Timolol (Blocadren) and
propranolol (Inderal) are FDA
approved
• Good choice for patients
with HTN, CAD, tremor, or
anxiety

Disadvantages
• Side effects =
fatigue, dizziness, depression
, exercise intolerance, may
worsen aura
• Avoid in patients with severe
asthma, depression, bradycar
dia, Raynaud's, overt CHF
Calcium Channel Blockers
. Although the mechanism by which calcium
channel antagonists affect migraine is not known,
. vasoconstriction , prevention of platelet
aggregation and alterations in release and reuptake
of serotonin.
. Several trials have indicated some benefit for
verapamil and flunarizine In recurrent migraine.

. Verapamil in doses of 80 to 160 mg 3 times a
day reduces the incidence of migraine with aura,
but it is not as useful in migraine without aura.
Tricyclic Antidepressants
• Amitriptyline (Elavil) 10-200 mg nightly
• Nortriptyline (Pamelor) 10-150 mg nightly
• Desipramine (Norpramin) 25-200 mg nightly

• Imipramine (Tofranil) 10-200 mg nightly
• Doxepin (Sinequan) 10-200 mg nightly
Lower end of dosage range is usually effective for
migraine prevention
Tricyclic Antidepressants
Advantages
• Inexpensive
• Once daily dosing
• Good choice for patients
with
insomnia, neuropathy, m
ood
disorders, fibromyalgia

Disadvantages
• None are FDA-approved
• Side effects = sedation,
weight gain, dry mouth,
urinary retention
• Avoid in sz disorder,
cardiac conduction
abnormalities, BPH
Other Antidepressants
• Efficacy not established in clinical trials
– Best for fluoxetine (Prozac) 20 mg daily
– Anectodal evidence for other SSRIs, trazodone,
mirtazapine, bupropion, venalfaxine, and
duloxetine

• Migraines are more likely to be poorly
controlled if mood disorders are untreated
NSAIDs
• Long-acting agents taken on a scheduled basis have low risk
of causing MOH
• Consider for patients who:
– Have other chronic pain conditions
– Frequently use short-acting NSAID for acute treatment
– Are at low risk for developing complications from daily NSAID

• Caution patients about exceeding maximum daily dose
• Limited evidence to support efficacy
NSAIDs
• Diclofenac 75 mg PO BID
• Naproxen 500 mg PO BID
• Meloxicam 7.5-15 mg PO daily

• Celecoxib 200 mg PO daily
• Aspirin 81-325 mg PO daily
– May be especially helpful for reducing aura
Antiepileptic Drugs (AEDs)
• FDA approved for migraine prevention
– Divalporex Sodium (Depakote)
– Topiramate (Topamax)
• Limited evidence for migraine prevention
–
–
–
–

Gabapentin (Neurontin)
Lamotrigine (Lamictal)
Levetiracetam (Keppra)
Zonisamide (Zonegran)
Divalproex Sodium (Depakote)
• Increases GABA and stabilizes nerve membrane
activation thresholds
• Dose = 500 - 1500 mg daily divided BID or TID
– ER formulation allows for once daily dosing

• NNT = 2.8 to 4.2 (to ↓ migraine frequency 50%)
• Therapeutic plasma concentration = 50-100 mg/L
Divalproex Side Effects
Common/dose related
• Tremor
• Drowsiness
• Nausea/vomiting
• Easy bruising
• Weight gain
• Nystagmus

Rare/idiosyncratic
• Hepatotoxicity
• Pancreatitis
• Alopecia
• Thrombocytopenia
• Agranulocytosis
• Rash (SJS)
• Suicidal behavior
Topiramate (Topamax) - MOA
• Not completely understood

• Blocks NMDA receptors
• Blocks voltage dependant sodium channels

• Enhances GABA
• Weakly inhibits carbonic anhydrase

.
Topiramate Dosing
• Dose titration in clinical trials:
– Initial dose = 25 mg daily
– Titrate by 25 mg every week
– No consistent additional benefit seen in doses >100 mg

• Dose titration in U of U Headache Clinic
–
–
–
–

Initial dose = 12.5 mg at bedtime
Titrate by 12.5 mg every week
Goal of 50 mg BID
May eventually increase up to 100 mg BID in certain patients
Topiramate Side Effects
Common
• Paresthesias
• Cognitive problems
• Fatigue
• Weight loss
• Dizziness
• Nausea
• Taste perversion

Rare or Serious
• Metabolic acidosis
• Depression
• Nephrolithiasis
• Glaucoma
• Oligohydrosis
• Suicidal behavior
Gabapentin (Neurontin)
• Mechanism of action
–
–
–
–

Enhances GABA activity
Binds to alpha-2-delta subunit of voltage gated calcium channels
Inhibits high-voltage-activated calcium currents
Result is decreased synaptic transmission

• Limited evidence from clinical trials for migraine
prevention
– NNT = 3 (50% reduction in migraine frequency)
– Only 2 RCT, did not use typical migraine outcomes

Vikelis and Rapoport. CNS Drugs 2010.
Botulinum Toxin
• Recently FDA approved for chronic migraine
• Dose = 155-195 units injected into muscles of
face, neck and head
• Mecahnism of Action (purposed)
– Blocks release of Substance P and CGRP
Inhibits peripheral signals to CNS and blocks
central sensitization

Dodick DW. Headache 2010.
Botulinum Toxin
• Efficacy
– Botulinum Toxin superior to placebo in 2 large,
double blind, randomized, controlled trials
– Botulinum Toxin similar to topiramate and
amitriptyline in small, shorter duration studies
– Botulinum toxin = placebo for episodic migraine

• Side effects = muscle weakness, injection site
pain, and “spread of toxin effect”
2. Tension-type headache

2.1
2.2
2.3
2.4

Infrequent episodic tension-type headache
Frequent episodic tension-type headache
Chronic tension-type headache
Probable tension-type headache

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
Tension Type Headache
• Occurs in up to 80% of the population

• Most patients treat with OTCs and do not seek
medical attention
• Pathophysiology unclear
– Theory of increased muscle tension is unproven

• Pain characteristics
– Bandlike, bilateral
– Extends form forehead to sides of temples
– Involves posterior neck muscles in cape-like distribution
Acute Treatment (Episodic TTH)
• First line: OTC analgesics (APAP, NSAIDs)
• Second line: ASA+APAP+caffeine, butalbital
containing products
• High risk of rebound headaches
• Limit acute treatment to 2-3 days per week
Preventive Treatment (Chronic TTH)
Non-Pharmacologic
• Proper sleep hygiene
• Stress management
• Acupuncture
• Biofeedback
• Physical therapy

Pharmacologic
• TCAs (best efficacy)
• SSRIs (better tolerated)

**Consider for patients with >15 headaches per month**
3. Cluster headache
and other trigeminal autonomic
cephalalgias

3. Cluster headache
and other trigeminal autonomic
3.1 Cluster headache
cephalalgias
3.2 Paroxysmal hemicrania

3.3 Short-lasting unilateral neuralgiform
headache attacks with conjunctival injection
and tearing (SUNCT)
3.4 Probable trigeminal autonomic cephalalgia
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
3.1 Cluster headache
A. At least 5 attacks fulfilling criteria B-D
B. Severe or very severe unilateral orbital, supraorbital
and/or temporal pain lasting 15-180 min if untreated
C. Headache is accompanied by 1 of the following:
1. ipsilateral conjunctival injection and/or lacrimation
2. ipsilateral nasal congestion and/or rhinorrhoea
3. ipsilateral eyelid oedema
4. ipsilateral forehead and facial sweating
5. ipsilateral miosis and/or ptosis
6. a sense of restlessness or agitation
D. Attacks have a frequency from 1/2 d to 8/d
E. Not attributed to another disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
3.1 Cluster headache
3.1.1 Episodic cluster headache
A. Attacks fulfilling criteria A-E for 3.1 Cluster
headache
B. At least two cluster periods lasting 7-365 d and
separated by pain-free remission periods of 1 mo

3.1.2 Chronic cluster headache
A. Attacks fulfilling criteria A-E for 3.1 Cluster
headache
B. Attacks recur over >1 y without remission periods
or with remission periods lasting <1 mo
Cluster Headache Abortive Treatment
• Inhalation of 100% oxygen up to 15 L/min

• Sumatriptan (Imitrex) 4-6mg subQ or 20 mg nasally
• Zolmitriptan (Zomig) 5-10 mg nasally or PO

• Dihdroergotamine (Migranal) 1 mg nasally up to 3 mg
in 24 hours
• Prednisone 40-100 mg burst and taper

Bajwa and Wootton. Up to Date 2007
Cluster Headache Prevention
• Verapamil 120-360 mg PO daily

• Lithium 300 mg PO BID to TID
• Divalproex 500-1500 mg PO daily to BID

• Topiramate 50-200 mg PO divided BID
• Prednisone 40-100 mg burst and taper
• Melatonin 3 mg PO QPM

Bajwa and Wootton. Up to Date 2007
The Headache Diary
• Pain score
• Characteristics of the pain
• Associated symptoms
• Acute treatments used and response

• Triggers
The Headache Diary
• Makes the patient responsible for their disease

• Aids in diagnosis and differentiating between headache
types
• Assesses efficacy of acute and preventive treatment
• Identifies triggers
• Minimizes recall bias
3.2 Paroxysmal hemicrania
A. At least 20 attacks fulfilling criteria B-D
B. Attacks of severe unilateral orbital, supraorbital or
temporal pain lasting 2-30 min
C. Headache is accompanied by 1 of the following:
1. ipsilateral conjunctival injection and/or lacrimation
2. ipsilateral nasal congestion and/or rhinorrhoea
3. ipsilateral eyelid oedema
4. ipsilateral forehead and facial sweating
5. ipsilateral miosis and/or ptosis
D. Attacks have a frequency >5/d for > half of the time,
although periods with lower frequency may occur
E. Attacks are prevented completely by therapeutic doses
of indomethacin
F. Not attributed to another disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
4. Other primary headaches
4.1 Primary stabbing headache
4.2 Primary cough headache
4.3 Primary exertional headache
4.4 Primary headache associated with sexual
activity
4.5 Hypnic headache
4.6 Primary thunderclap headache
4.7 Hemicrania continua
4.8 New daily-persistent headache (NDPH)
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
4.5 Hypnic headache

New entrant to classification
A. Dull headache fulfilling criteria B-D
B. Develops only during sleep, and awakens patient
C. At least two of the following characteristics:
New entrant to classification
1. occurs >15 times/mo
2. lasts 15 min after waking
3. first occurs after age of 50 y
D. No autonomic symptoms and no more than one of
nausea, photophobia or phonophobia
E. Not attributed to another disorder

4.5 Hypnic headache

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
4.6 Primary thunderclap
headache
A. Severe head pain fulfilling criteria B and C
B. Both of the following characteristics:
1. sudden onset, reaching maximum intensity in <1 min
2. lasting from 1 h to 10 d
C. Does not recur regularly over subsequent weeks or
months
D. Not attributed to another disorder

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
4.7 Hemicrania continua
New entrant to classification

A. Headache for >3 mo fulfilling criteria B-D
B. All of the following characteristics:
1. unilateral pain without side-shift
2. daily and continuous, without pain-free periods
3. moderate intensity, with exacerbations of severe pain
C. At least one of the following autonomic features occurs
during exacerbations, ipsilateral to the pain:
1. conjunctival injection and/or lacrimation
2. nasal congestion and/or rhinorrhoea
3. ptosis and/or miosis
D. Complete response to therapeutic doses of indomethacin
E. Not attributed to another disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
4.8 New daily-persistent headache
New entrant to classification

A. Headache for >3 mo fulfilling criteria B-D
B. Headache is daily and unremitting from onset or from
<3 d from onset
C. At least two of the following pain characteristics:
New entrant to classification
1. bilateral location
2. pressing/tightening (non-pulsating) quality
3. mild or moderate intensity
4. not aggravated by routine physical activity
D. Both of the following:
1. not >1 of photophobia, phonophobia or mild nausea
2. neither moderate or severe nausea nor vomiting
E. Not attributed to another disorder

4.8 New daily-persistent headache

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
Primary Chronic Daily Headache Disorders of Long-Duration (>4 h)
Disorder

Demographic

Clinical Features

Recommended Treatments

Chronic migraine

Headache ≥15 days per month
for >3 mo, of which ≥8 days
Female/male, 3 : 1 Prevalence
Topiramate, divalproex sodium,
meet ICHD-II criteria for
2%
amitriptyline
migraine without aura or relief
with triptan or ergot

Mild-moderate severity; no
Chronic tension-type headache Equal sex ratio Prevalence 2% migrainous symptoms; bilateral, Amitriptyline
nonthrobbing

New daily persistent headache Female > male

Bilateral, persistent, moderately
severe; may be preceded by
viral infection; may resemble
Amitriptyline
migraine or tension-type
headache

Hemicrania continua

Rare; unilateral, constant,
exacerbations of severe
headache, cranial autonomic
Indomethacin
symptoms, and ice-pick pain;
responsive to indomethacin by
definition

Female > male
Diagnostic criteria
for secondary headaches
A. Headache with one (or more) of the following [listed]
characteristics and fulfilling criteria C and D
B. Another disorder known to be able to cause headache
has been demonstrated
C. Headache occurs in close temporal relation to the
other disorder and/or there is other evidence of a
causal relationship
D. Headache is greatly reduced or resolves within 3 mo
(shorter for some disorders) after successful treatment
or spontaneous remission of the causative disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
6. Headache attributed to cranial
or cervical vascular disorder
6.1 Headache attributed to ischaemic stroke or
transient ischaemic attack
6.2 Headache attributed to non-traumatic intracranial
haemorrhage
6.3 Headache attributed to unruptured vascular
malformation
6.4 Headache attributed to arteritis
6.5 Carotid or vertebral artery pain
6.6 Headache attributed to cerebral venous thrombosis
6.7 Headache attributed to other intracranial vascular
disorder
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
6.4.1 Headache attributed to giant
cell arteritis
A. Any new persisting headache fulfilling criteria C and D
B. At least one of the following:
1. swollen tender scalp artery with elevated
erythrocyte sedimentation rate (ESR) and/or
C reactive protein (CRP)
2. temporal artery biopsy demonstrating giant cell
arteritis
C. Headache develops in close temporal relation to other
symptoms and signs of giant cell arteritis
D. Headache resolves or greatly improves within 3 d of
high-dose steroid treatment
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
6.7.1 CADASIL
A. Attacks of migraine with aura, with or without other
neurological signs
B. Typical white matter changes on MRI T2WI
C. Diagnostic confirmation from skin biopsy evidence or
genetic testing (Notch 3 mutations)

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
7.4.2 Headache attributed
directly to neoplasm
A. Headache with 1 of the following characteristics and
fulfilling criteria C and D:
1. progressive
2. localised
3. worse in the morning
4. aggravated by coughing or bending forward
B. Intracranial neoplasm shown by imaging
C. Headache develops in temporal (and usually spatial)
relation to the neoplasm
D. Headache resolves within 7 d after surgical removal
or volume-reduction of neoplasm or treatment with
corticosteroids
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
9.1 Headache attributed to
intracranial infection
9.1.1 Headache attributed to bacterial meningitis
9.1.2 Headache attributed to lymphocytic
meningitis
9.1.3 Headache attributed to encephalitis
9.1.4 Headache attributed to brain abscess
9.1.5 Headache attributed to subdural empyema

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
9.1.1 Headache attributed to
bacterial meningitis
A. Headache with 1 of the following characteristics and
fulfilling criteria C and D:
1. diffuse pain
2. intensity increasing to severe
3. associated with nausea, photophobia and/or
phonophobia
B. Evidence of bacterial meningitis from examination of CSF
C. Headache develops during the meningitis
D. One or other of the following:
1. headache resolves within 3 mo after relief from
meningitis
2. headache persists but 3 mo have not yet passed since
relief from meningitis

9.1.1 Headache attributed to
bacterial meningitis

ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
9.1.1 Headache attributed to
bacterial meningitis
Notes

• Criterion D does not relate to evidence of causation
• Causation is established by onset during diagnosed
bacterial meningitis, whilst it is well recognised that
this headache often persists
• When this occurs, 9.4.1 Chronic post-bacterial
meningitis headache is diagnosed
• Criterion D2 allows a default diagnosis within 3 mo,
before it is known whether headache will resolve or
persist
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
9.2 Headache attributed to
systemic infection
A. Headache with 1 of the following characteristics and
fulfilling criteria C and D:
1. diffuse pain
2. intensity increasing to moderate or severe
3. associated with fever, general malaise or other
symptoms of systemic infection
B. Evidence of systemic infection
C. Headache develops during the systemic infection
D. Headache resolves within 72 h after effective
treatment of the infection
ICHD-II. Cephalalgia 2004; 24 (Suppl 1)

©International Headache Society 2003/4
Headache ppt
Headache ppt
Headache ppt

Más contenido relacionado

La actualidad más candente (20)

Guillain Barre Syndrome
Guillain Barre SyndromeGuillain Barre Syndrome
Guillain Barre Syndrome
 
History taking in neurology 2012
History taking in neurology 2012History taking in neurology 2012
History taking in neurology 2012
 
Status Epilepticus
Status EpilepticusStatus Epilepticus
Status Epilepticus
 
Vertigo
VertigoVertigo
Vertigo
 
Bell’s palsy
Bell’s palsyBell’s palsy
Bell’s palsy
 
Migraine and types
Migraine and typesMigraine and types
Migraine and types
 
Practical Approach to headache
Practical  Approach to headachePractical  Approach to headache
Practical Approach to headache
 
Hemiplegia (1)
Hemiplegia (1)Hemiplegia (1)
Hemiplegia (1)
 
Myasthenia Gravis
Myasthenia GravisMyasthenia Gravis
Myasthenia Gravis
 
TB Meningitis
TB MeningitisTB Meningitis
TB Meningitis
 
CNS examination
CNS examinationCNS examination
CNS examination
 
Headache (tension type headache, migraine)
Headache (tension type headache, migraine)Headache (tension type headache, migraine)
Headache (tension type headache, migraine)
 
Bells palsy
Bells palsyBells palsy
Bells palsy
 
Hemorrhagic stroke
Hemorrhagic stroke Hemorrhagic stroke
Hemorrhagic stroke
 
Tension Type Headache (TTH)
Tension Type Headache (TTH)Tension Type Headache (TTH)
Tension Type Headache (TTH)
 
Benign Paroxysmal Positional Vertigo (BPPV)
Benign Paroxysmal Positional Vertigo (BPPV)Benign Paroxysmal Positional Vertigo (BPPV)
Benign Paroxysmal Positional Vertigo (BPPV)
 
Myasthenia gravis
Myasthenia gravisMyasthenia gravis
Myasthenia gravis
 
Hemiplegia
HemiplegiaHemiplegia
Hemiplegia
 
Tremors
TremorsTremors
Tremors
 
Dizziness
DizzinessDizziness
Dizziness
 

Destacado (7)

Approach to headache
Approach to headacheApproach to headache
Approach to headache
 
Headache
HeadacheHeadache
Headache
 
Stroke
StrokeStroke
Stroke
 
Headaches Lecture
Headaches LectureHeadaches Lecture
Headaches Lecture
 
Headache
HeadacheHeadache
Headache
 
Head trauma & Management
Head trauma & ManagementHead trauma & Management
Head trauma & Management
 
Stroke
StrokeStroke
Stroke
 

Similar a Headache ppt

Similar a Headache ppt (20)

Recent Migraine Headache Approach and Treatment.pptx
Recent Migraine Headache Approach and Treatment.pptxRecent Migraine Headache Approach and Treatment.pptx
Recent Migraine Headache Approach and Treatment.pptx
 
Seminar rare headache syndromes
Seminar rare headache syndromesSeminar rare headache syndromes
Seminar rare headache syndromes
 
Headache in clinical practice
Headache in clinical practiceHeadache in clinical practice
Headache in clinical practice
 
HEADCHE : Migraine
HEADCHE : Migraine HEADCHE : Migraine
HEADCHE : Migraine
 
Ichdii cranial
Ichdii cranialIchdii cranial
Ichdii cranial
 
Headache
HeadacheHeadache
Headache
 
Pathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadachePathophysiology: Migraine & Headache
Pathophysiology: Migraine & Headache
 
Headache with Special Reference to Migraine
Headache with Special Reference to MigraineHeadache with Special Reference to Migraine
Headache with Special Reference to Migraine
 
Approach to patient_with_headache_in_ed
Approach to patient_with_headache_in_edApproach to patient_with_headache_in_ed
Approach to patient_with_headache_in_ed
 
Migraine headache
Migraine headacheMigraine headache
Migraine headache
 
Clinical study of Migraine
Clinical study of MigraineClinical study of Migraine
Clinical study of Migraine
 
HEADACHE.pptx
HEADACHE.pptxHEADACHE.pptx
HEADACHE.pptx
 
Headache ; dr jayesh
Headache  ; dr jayeshHeadache  ; dr jayesh
Headache ; dr jayesh
 
Headache
Headache Headache
Headache
 
Headache other than migraine
Headache other than migraineHeadache other than migraine
Headache other than migraine
 
Migraine in children by Rafi
Migraine in children by RafiMigraine in children by Rafi
Migraine in children by Rafi
 
Headache
HeadacheHeadache
Headache
 
Lecture on Pediatric headache.pptx
Lecture on Pediatric headache.pptxLecture on Pediatric headache.pptx
Lecture on Pediatric headache.pptx
 
Neuropsychiatric Aspects of Headache.pptx
Neuropsychiatric Aspects of Headache.pptxNeuropsychiatric Aspects of Headache.pptx
Neuropsychiatric Aspects of Headache.pptx
 
Headache evaluation.
Headache evaluation.Headache evaluation.
Headache evaluation.
 

Más de Dr Surendra Khosya

Recent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of EpilepsyRecent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of EpilepsyDr Surendra Khosya
 
Violence against doctors: A viral epidemic ?
Violence against doctors: A viral epidemic ?Violence against doctors: A viral epidemic ?
Violence against doctors: A viral epidemic ?Dr Surendra Khosya
 
Approach to acute stroke BE FAST
Approach to acute stroke BE FASTApproach to acute stroke BE FAST
Approach to acute stroke BE FASTDr Surendra Khosya
 
INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...
INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...
INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...Dr Surendra Khosya
 
Approach to temporal lobe anatomy,function,epilepsy MRI finding
Approach to temporal lobe anatomy,function,epilepsy MRI findingApproach to temporal lobe anatomy,function,epilepsy MRI finding
Approach to temporal lobe anatomy,function,epilepsy MRI findingDr Surendra Khosya
 
Cerebellum and afferent ayaxia
Cerebellum and afferent ayaxiaCerebellum and afferent ayaxia
Cerebellum and afferent ayaxiaDr Surendra Khosya
 
new gene and new target in alzheimer disease
new gene and new target in alzheimer diseasenew gene and new target in alzheimer disease
new gene and new target in alzheimer diseaseDr Surendra Khosya
 
approach to Language dysfunction and speech disorder
approach to Language dysfunction and speech disorderapproach to Language dysfunction and speech disorder
approach to Language dysfunction and speech disorderDr Surendra Khosya
 
Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Dr Surendra Khosya
 
Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Dr Surendra Khosya
 

Más de Dr Surendra Khosya (14)

Final ppt epilepsy
Final ppt epilepsyFinal ppt epilepsy
Final ppt epilepsy
 
Recent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of EpilepsyRecent Advances in The Treatment of Epilepsy
Recent Advances in The Treatment of Epilepsy
 
Violence against doctors: A viral epidemic ?
Violence against doctors: A viral epidemic ?Violence against doctors: A viral epidemic ?
Violence against doctors: A viral epidemic ?
 
Novel coronavirus(2019 n cov)
Novel coronavirus(2019 n cov)Novel coronavirus(2019 n cov)
Novel coronavirus(2019 n cov)
 
Approach to acute stroke BE FAST
Approach to acute stroke BE FASTApproach to acute stroke BE FAST
Approach to acute stroke BE FAST
 
INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...
INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...
INTERACT-2 (SAMURAI-ICH)early blood pressure (BP) variability and clinical ou...
 
Approach to temporal lobe anatomy,function,epilepsy MRI finding
Approach to temporal lobe anatomy,function,epilepsy MRI findingApproach to temporal lobe anatomy,function,epilepsy MRI finding
Approach to temporal lobe anatomy,function,epilepsy MRI finding
 
Cerebellum and afferent ayaxia
Cerebellum and afferent ayaxiaCerebellum and afferent ayaxia
Cerebellum and afferent ayaxia
 
new gene and new target in alzheimer disease
new gene and new target in alzheimer diseasenew gene and new target in alzheimer disease
new gene and new target in alzheimer disease
 
Approach to temporal lobe
Approach to temporal lobeApproach to temporal lobe
Approach to temporal lobe
 
approach to Language dysfunction and speech disorder
approach to Language dysfunction and speech disorderapproach to Language dysfunction and speech disorder
approach to Language dysfunction and speech disorder
 
Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD)
 
Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD)
 
Epilepsia ppt
Epilepsia ppt Epilepsia ppt
Epilepsia ppt
 

Último

Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)Mohamed Rizk Khodair
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...Ganesan Yogananthem
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 

Último (20)

Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 

Headache ppt

  • 1. Origins of Pain in the Head • Extra-cranial pain sensitive structures: – – – – – – – Sinuses Eyes/orbits Ears Teeth TMJ Blood vessels 5,7,9,10 cranial nerves carry pain from thes strucure • Intra-cranial pain sensitive structures: – Arteries of circle of willis and proximal dural arteries, – Dural Venous sinuses,veins – Meninges – Dura
  • 2. Classification of Headaches • PRIMARY - NO structural or metabolic abnormality: – Tension – Migraine – Cluster • SECONDARY – structural or metabolic abnormality: – Extracranial: sinusitis, otitis media, glaucoma, TMJ ds – Inracranial: SAH, vasculitis, dissection, ce ntral vein thrombosis, tumor, abscess, meningitis – Metabolic disorders: CO2 retention, CO poisoing
  • 3. RED Flags • • • • • • • • New onset headache in a patient >50 y.o. Sudden, worst headache of one’s life Morning headache associated with N/V Fever, weight loss Worsens with valsalva maneuvers Focal neurologic deficits, jaw claudication Altered LOC Hx of trauma, cancer or HIV
  • 4. Part 1: The primary headaches 1. Migraine 2. Tension-type headache 3. Cluster headache and other trigeminal autonomic cephalalgias 4. Other primary headaches ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 5. Primary Headache Types Migraine Tension Pain Throbbing, mod Pressure, t Description erate to ightness, severe, worse waxes and w/exertion wanes Associated Photo/phonoSymptoms phobia, n/v, aura Bajwa and Wootton. Up to Date 2007 None Cluster Abrupt onset, deep, continuous, excruciating, explosive Tearing, congestion, rhinorrhea, pallor, sweating
  • 6. Primary Headache Types Migraine Location Duration Patient Appearance Tension Cluster 60-70% unilateral 4-72 hr Bilateral Unilateral 0.5-3 hr, many per day Resting in Remains Remains quiet dark active or active, prefers room; young prefers to hot shower, female rest male, smoker Bajwa and Wootton. Up to Date 2007 Variable
  • 7. 1. Migraine 1.1 Migraine without aura 1.2 Migraine with aura 1.3 Childhood periodic syndromes that are commonly precursors of migraine 1.4 Retinal migraine 1.5 Complications of migraine 1.6 Probable migraine ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 8. Pathophysiology • Brainstem neuronal hyperexcitability • Cortical spreading depression w/aura • Abnormalities of 5-HT, CGRP, NE, DA, GABA, glutamate, NO, and endorphins • Trigeminal Activation Marcus, DA. Headache Simplified 2008.
  • 9. Presymptomatic hyperexcitabilty increases brain stem response to triggers Release of Neurotransmitters (5-HT, NE, DA, GABA, Glutamate, NO, CGRP, Substance P, Estrogen) Neurotransmitters activate the Trigeminal Nucleus Dilation of Meningeal blood vessels (Throbbing) Activation of Area Postrema (N/V) Activation of Hypothalamus (Hypersensitivity) Activation of Cortex and Thalamus (Head pain) Marcus, DA. Headache Simplified 2008. Activation of cervical trigeminal system (Muscle spasm)
  • 10. 1.1 Migraine without aura A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 h (untreated or unsuccessfully treated) C. Headache has 2 of the following characteristics: 1. unilateral location 2. pulsating quality 3. moderate or severe pain intensity 4. aggravation by or causing avoidance of routine physical activity (eg, walking, climbing stairs) D. During headache 1 of the following: 1. nausea and/or vomiting 2. photophobia and phonophobia E. Not attributed to another disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 11. 1.1 Migraine without aura Notes • If <5 attacks but criteria B-E otherwise met, code as 1.6.1 Probable migraine without aura • When attacks occur on 15 d/mo for >3 mo, code as Notes 1.1 Migraine without aura + 1.5.1 Chronic migraine • Pulsating means varying with the heartbeat • In children: – attacks may last 1-72 h – occipital headache requires caution • In young children: – photophobia and/or phonophobia may be inferred from their behaviour 1.1 Migraine without aura ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 12. ‘Not attributed to another disorder’ Note For all primary headaches, this criterion means: • History and physical/neurological examinations do not suggest any of the disorders listed in groups 5-12, or history and/or physical/ neurological examinations do suggest such disorder but it is ruled out by appropriate investigations, or such disorder is present but headache does not occur for the first time in close temporal relation to the disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 13. 1.2 Migraine with aura 1.2.1 1.2.2 1.2.3 1.2.4 1.2.5 1.2.6 Typical aura with migraine headache 1.2 aura with non-migraine headache TypicalMigraine with aura Typical aura without headache Familial hemiplegic migraine (FHM) Sporadic hemiplegic migraine Basilar-type migraine ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 14. 1.2 Migraine with aura A. At least 2 attacks fulfilling criterion B 1.2 Migraine with aura B. Migraine aura fulfilling criteria B and C for one of the subforms 1.2.1-1.2.6 C. Not attributed to another disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 15. 1.2 Migraine with aura Subtypes new to classification 1.2.1 Typical aura with migraine headache • 1.2 Migraine with with headache aura most migraine auras are associated Subtypes new to classification fulfilling criteria for 1.1 Migraine without aura 1.2.2 Typical aura with non-migraine headache 1.2.3 Typical aura without headache • migraine aura is sometimes associated with a headache that does not fulfil these criteria • or occurs without headache ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 16. 1.2.1 Typical aura with migraine headache A. At least 2 attacks fulfilling criteria B–D B. Aura consisting of 1 of the following, but no motor weakness: 1. fully reversible visual symptoms including positive and/or negative features 2. fully reversible sensory symptoms including positive and/or negative features 3. fully reversible dysphasic speech disturbance 1.2.1 Typical aura with migraine headache ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 17. 1.2.1 Typical aura with migraine headache C. At least two of the following: 1. homonymous visual symptoms and/or unilateral sensory symptoms 2. at least one aura symptom develops gradually over 5 min and/or different aura symptoms occur in succession over 5 min 3. each symptom lasts 5 and 60 min D. Headache fulfilling criteria B-D for 1.1 Migraine without aura begins during the aura or follows aura within 60 min E. Not attributed to another disorder 1.2.1 Typical aura with migraine headache ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 18. 1.2.2 Typical aura with non-migraine headache As 1.2.1 except: D. Headache that does not fulfil criteria B-D for 1.1 Migraine without aura begins during the aura or follows aura within 60 min ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 19. 1.2.3 Typical aura without headache 1.2.3 Typical aura without headache As 1.2.1 except: D. Headache does not occur during aura nor follow aura within 60 min ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 20. 1.2.4 Familial hemiplegic migraine (FHM) A. At least 2 attacks fulfilling criteria B and C B. Aura consisting of fully reversible motor weakness and 1 of: 1. fully reversible visual symptoms including positive and/or negative features 2. fully reversible sensory symptoms including positive and/or negative features 3. fully reversible dysphasic speech disturbance ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 21. 1.2.6 Basilar-type migraine As 1.2.1 except: B. Aura consisting of 2 of the following fully reversible symptoms, but no motor weakness: 1. dysarthria; 2. vertigo; 3. tinnitus; 4. hypacusia; 5. diplopia; 6. visual symptoms simultaneously in both temporal and nasal fields of both eyes; 7. ataxia; 8. decreased level of consciousness; 9. simultaneously bilateral paraesthesias C. At least one of the following: 1. at least one one aura symptom develops gradually over 5 min and/or different aura symptoms occur in succession over 5 min 2. each aura symptom lasts 5 and 60 min ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 22. 1.3 Childhood periodic syndromes that are commonly precursors of migraine 1.3.1 Cyclical vomiting 1.3.2 Abdominal migraine 1.3.3 Benign paroxysmal vertigo of childhood ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 23. 1.3.2 Abdominal migraine A. At least 5 attacks fulfilling criteria B-D B. Attacks of abdominal pain lasting 1-72 h C. Abdominal pain has all of the following characteristics: 1. midline location, periumbilical or poorly localised 2. dull or “just sore” quality 3. moderate or severe intensity D. During abdominal pain 2 of the following: 1. anorexia; 2. nausea; 3. vomiting; 4. pallor E. Not attributed to another disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 24. Types of Migraine Treatment • Acute – Taken during an attack – Reduces pain, associated symptoms and disability and stops progression • Preventive – Taken daily for months to years – Reduces frequency, severity, and duration – Used in addition to acute treatments .
  • 25. Acute Treatment Principles • Treat attacks rapidly and consistently • Tailor treatment to the patient and the sx • Minimize adverse events and cost • Limit to 3 days per week or less
  • 26. Antiemetics • Prevent and treat nausea • Improve GI motility • Enhance absorption of other anti-migraine medications • Limited RCT to support their use in migraine
  • 27. Phenothiazines • Promethazine (Phenergan) – Available PO, IM, PR – Dose = 25-50 mg Q6H PRN – Blocks dopamine and histamine receptors • Prochlorperazine (Compazine) – Available PO, IM, IV, PR – Dose = 5-10 mg Q6H PRN – Blocks dopamine receptors • SE = sedation, dizziness, dystonic rxn
  • 29. Acute Treatment - Triptans Fast onset/short duration • Sumatriptan • Rizatriptan • Zomitriptan • Almotriptan • Eletriptan • Treximet (Suma + Naproxen) Slow onset/long duration • Naratriptan • Frovatriptan
  • 30. Acute Treatment - Triptans • Reasonable first choice for patients with moderate to severe disability from migraines • Limit use to 2-3 days per week • Patients who fail one triptan often respond to another • Do not use one triptan within 24 hours of another
  • 31. Acute Treatment - Triptans Mechanism of action • 5HT-1B/1D agonists • Inhibit release of CGRP & substance P • Inhibit activation of the trigeminal nerve • Inhibit vasodilation in the meninges Johnston et al Drugs 2010 Loder NEJM 2010 Precautions • Ischemic heart dz or stroke • High risk for CAD • Pregnancy • Hemiplegic or basilar migraine • Ergots • Use w/ SSRIs?
  • 32. Triptan Side Effects • • • • • • • Flushing, feeling or warmth Chest pressure or heaviness Throat tightness Paresthesias Dizziness, fatigue, drowsiness Nausea Intolerable taste with nasal formulations Johnston et al Drugs 2010 Loder NEJM 2010
  • 33. Triptan Comparison Drug Tmax (h) T1/2 (h) Metabolism Sumatriptan 50 &100 mg tablets 2.5 2 MAO-A Sumatriptan 20 mg nasal 1 2 Sumatriptan 6 mg subQ 0.16-0.2 2 Zolmitriptan 2.5 mg tab 2 3 Zolmitriptan 2.5 mg ODT 3.3 2.5-3 Zolmitriptan 5 mg nasal 4 2.82 Rizatriptan 10 mg tab 1.2 2 Rizatriptan 10 mg ODT 1.6-2.5 2 Naratriptan 2-3 5-6 P450, 50% unchanged Almotriptan 1.4-3.8 3.2-3.7 MAO-A, 3A4, and 2D6 Frovatriptan 2-4 26 Mostly unchanged Eletriptan 1-2 3.6-5.5 3A4 2D6 and MAO-A MAO-A
  • 34. Acute Treatment – Ergots • Mechanism of Action – Constrict peripheral and cranial blood vessels – Bind to 5HT, NE, DA, alpha and beta receptors • Contraindications and precautions – CAD or CVD (or high risk), uncontrolled HTN – Hemiplegic or basilar migraine – Pregnancy (category X) and breast feeding – Drugs metabolized by CYP3A4, triptans
  • 35. Ergot Side Effects • Nausea and vomiting (pre-treat with antiemetic) • Coronary artery spasm, angina, MI • Tingling, numbness, Dizziness • Increased BP and HR • “Ergotism”
  • 36. Choosing Acute Rx Early N/V Recurrence • Nasal triptans • Sumatriptan SubQ • ODT triptans? • Nara, Frova, Almotriptan • Ergots • Triptan + NSAID Sensitive to SE Rapid Onset • Naratriptan • Frovatriptan • Almotriptan • Sumatriptan SubQ • Nasal Triptans • DHE nasal or IM
  • 37. Indications for a Preventive Agent • Migraine-related disability > 3d/month • Migraines last over 48 hours • Acute treatments are contraindicated, ineffective, or overused • Migraines cause profound disability or prolonged aura • Patient preference
  • 38. Beta Blockers • FDA approved for migraine prevention – Propranolol (Inderal) 60-240 mg PO once daily for ER or divided BID or TID for IR – Timolol (Blocadren) 10-30 mg PO daily in 2 divided doses • Limited evidence for migraine prevention – Nadolol (Corgard) 20-240 mg PO once daily – Atenolol (Tenormin) 50-150 mg PO daily or divided BID – Metoprolol (Lotensin, Toprol XL) 100-200 mg daily or divided BID for IR formulation
  • 39. Beta Blockers Advantages • Thoroughly studied and widely used • Timolol (Blocadren) and propranolol (Inderal) are FDA approved • Good choice for patients with HTN, CAD, tremor, or anxiety Disadvantages • Side effects = fatigue, dizziness, depression , exercise intolerance, may worsen aura • Avoid in patients with severe asthma, depression, bradycar dia, Raynaud's, overt CHF
  • 40. Calcium Channel Blockers . Although the mechanism by which calcium channel antagonists affect migraine is not known, . vasoconstriction , prevention of platelet aggregation and alterations in release and reuptake of serotonin. . Several trials have indicated some benefit for verapamil and flunarizine In recurrent migraine. . Verapamil in doses of 80 to 160 mg 3 times a day reduces the incidence of migraine with aura, but it is not as useful in migraine without aura.
  • 41. Tricyclic Antidepressants • Amitriptyline (Elavil) 10-200 mg nightly • Nortriptyline (Pamelor) 10-150 mg nightly • Desipramine (Norpramin) 25-200 mg nightly • Imipramine (Tofranil) 10-200 mg nightly • Doxepin (Sinequan) 10-200 mg nightly Lower end of dosage range is usually effective for migraine prevention
  • 42. Tricyclic Antidepressants Advantages • Inexpensive • Once daily dosing • Good choice for patients with insomnia, neuropathy, m ood disorders, fibromyalgia Disadvantages • None are FDA-approved • Side effects = sedation, weight gain, dry mouth, urinary retention • Avoid in sz disorder, cardiac conduction abnormalities, BPH
  • 43. Other Antidepressants • Efficacy not established in clinical trials – Best for fluoxetine (Prozac) 20 mg daily – Anectodal evidence for other SSRIs, trazodone, mirtazapine, bupropion, venalfaxine, and duloxetine • Migraines are more likely to be poorly controlled if mood disorders are untreated
  • 44. NSAIDs • Long-acting agents taken on a scheduled basis have low risk of causing MOH • Consider for patients who: – Have other chronic pain conditions – Frequently use short-acting NSAID for acute treatment – Are at low risk for developing complications from daily NSAID • Caution patients about exceeding maximum daily dose • Limited evidence to support efficacy
  • 45. NSAIDs • Diclofenac 75 mg PO BID • Naproxen 500 mg PO BID • Meloxicam 7.5-15 mg PO daily • Celecoxib 200 mg PO daily • Aspirin 81-325 mg PO daily – May be especially helpful for reducing aura
  • 46. Antiepileptic Drugs (AEDs) • FDA approved for migraine prevention – Divalporex Sodium (Depakote) – Topiramate (Topamax) • Limited evidence for migraine prevention – – – – Gabapentin (Neurontin) Lamotrigine (Lamictal) Levetiracetam (Keppra) Zonisamide (Zonegran)
  • 47. Divalproex Sodium (Depakote) • Increases GABA and stabilizes nerve membrane activation thresholds • Dose = 500 - 1500 mg daily divided BID or TID – ER formulation allows for once daily dosing • NNT = 2.8 to 4.2 (to ↓ migraine frequency 50%) • Therapeutic plasma concentration = 50-100 mg/L
  • 48. Divalproex Side Effects Common/dose related • Tremor • Drowsiness • Nausea/vomiting • Easy bruising • Weight gain • Nystagmus Rare/idiosyncratic • Hepatotoxicity • Pancreatitis • Alopecia • Thrombocytopenia • Agranulocytosis • Rash (SJS) • Suicidal behavior
  • 49. Topiramate (Topamax) - MOA • Not completely understood • Blocks NMDA receptors • Blocks voltage dependant sodium channels • Enhances GABA • Weakly inhibits carbonic anhydrase .
  • 50. Topiramate Dosing • Dose titration in clinical trials: – Initial dose = 25 mg daily – Titrate by 25 mg every week – No consistent additional benefit seen in doses >100 mg • Dose titration in U of U Headache Clinic – – – – Initial dose = 12.5 mg at bedtime Titrate by 12.5 mg every week Goal of 50 mg BID May eventually increase up to 100 mg BID in certain patients
  • 51. Topiramate Side Effects Common • Paresthesias • Cognitive problems • Fatigue • Weight loss • Dizziness • Nausea • Taste perversion Rare or Serious • Metabolic acidosis • Depression • Nephrolithiasis • Glaucoma • Oligohydrosis • Suicidal behavior
  • 52. Gabapentin (Neurontin) • Mechanism of action – – – – Enhances GABA activity Binds to alpha-2-delta subunit of voltage gated calcium channels Inhibits high-voltage-activated calcium currents Result is decreased synaptic transmission • Limited evidence from clinical trials for migraine prevention – NNT = 3 (50% reduction in migraine frequency) – Only 2 RCT, did not use typical migraine outcomes Vikelis and Rapoport. CNS Drugs 2010.
  • 53. Botulinum Toxin • Recently FDA approved for chronic migraine • Dose = 155-195 units injected into muscles of face, neck and head • Mecahnism of Action (purposed) – Blocks release of Substance P and CGRP Inhibits peripheral signals to CNS and blocks central sensitization Dodick DW. Headache 2010.
  • 54. Botulinum Toxin • Efficacy – Botulinum Toxin superior to placebo in 2 large, double blind, randomized, controlled trials – Botulinum Toxin similar to topiramate and amitriptyline in small, shorter duration studies – Botulinum toxin = placebo for episodic migraine • Side effects = muscle weakness, injection site pain, and “spread of toxin effect”
  • 55. 2. Tension-type headache 2.1 2.2 2.3 2.4 Infrequent episodic tension-type headache Frequent episodic tension-type headache Chronic tension-type headache Probable tension-type headache ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 56. Tension Type Headache • Occurs in up to 80% of the population • Most patients treat with OTCs and do not seek medical attention • Pathophysiology unclear – Theory of increased muscle tension is unproven • Pain characteristics – Bandlike, bilateral – Extends form forehead to sides of temples – Involves posterior neck muscles in cape-like distribution
  • 57. Acute Treatment (Episodic TTH) • First line: OTC analgesics (APAP, NSAIDs) • Second line: ASA+APAP+caffeine, butalbital containing products • High risk of rebound headaches • Limit acute treatment to 2-3 days per week
  • 58. Preventive Treatment (Chronic TTH) Non-Pharmacologic • Proper sleep hygiene • Stress management • Acupuncture • Biofeedback • Physical therapy Pharmacologic • TCAs (best efficacy) • SSRIs (better tolerated) **Consider for patients with >15 headaches per month**
  • 59. 3. Cluster headache and other trigeminal autonomic cephalalgias 3. Cluster headache and other trigeminal autonomic 3.1 Cluster headache cephalalgias 3.2 Paroxysmal hemicrania 3.3 Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) 3.4 Probable trigeminal autonomic cephalalgia ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 60. 3.1 Cluster headache A. At least 5 attacks fulfilling criteria B-D B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15-180 min if untreated C. Headache is accompanied by 1 of the following: 1. ipsilateral conjunctival injection and/or lacrimation 2. ipsilateral nasal congestion and/or rhinorrhoea 3. ipsilateral eyelid oedema 4. ipsilateral forehead and facial sweating 5. ipsilateral miosis and/or ptosis 6. a sense of restlessness or agitation D. Attacks have a frequency from 1/2 d to 8/d E. Not attributed to another disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 61. 3.1 Cluster headache 3.1.1 Episodic cluster headache A. Attacks fulfilling criteria A-E for 3.1 Cluster headache B. At least two cluster periods lasting 7-365 d and separated by pain-free remission periods of 1 mo 3.1.2 Chronic cluster headache A. Attacks fulfilling criteria A-E for 3.1 Cluster headache B. Attacks recur over >1 y without remission periods or with remission periods lasting <1 mo
  • 62. Cluster Headache Abortive Treatment • Inhalation of 100% oxygen up to 15 L/min • Sumatriptan (Imitrex) 4-6mg subQ or 20 mg nasally • Zolmitriptan (Zomig) 5-10 mg nasally or PO • Dihdroergotamine (Migranal) 1 mg nasally up to 3 mg in 24 hours • Prednisone 40-100 mg burst and taper Bajwa and Wootton. Up to Date 2007
  • 63. Cluster Headache Prevention • Verapamil 120-360 mg PO daily • Lithium 300 mg PO BID to TID • Divalproex 500-1500 mg PO daily to BID • Topiramate 50-200 mg PO divided BID • Prednisone 40-100 mg burst and taper • Melatonin 3 mg PO QPM Bajwa and Wootton. Up to Date 2007
  • 64. The Headache Diary • Pain score • Characteristics of the pain • Associated symptoms • Acute treatments used and response • Triggers
  • 65. The Headache Diary • Makes the patient responsible for their disease • Aids in diagnosis and differentiating between headache types • Assesses efficacy of acute and preventive treatment • Identifies triggers • Minimizes recall bias
  • 66. 3.2 Paroxysmal hemicrania A. At least 20 attacks fulfilling criteria B-D B. Attacks of severe unilateral orbital, supraorbital or temporal pain lasting 2-30 min C. Headache is accompanied by 1 of the following: 1. ipsilateral conjunctival injection and/or lacrimation 2. ipsilateral nasal congestion and/or rhinorrhoea 3. ipsilateral eyelid oedema 4. ipsilateral forehead and facial sweating 5. ipsilateral miosis and/or ptosis D. Attacks have a frequency >5/d for > half of the time, although periods with lower frequency may occur E. Attacks are prevented completely by therapeutic doses of indomethacin F. Not attributed to another disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 67. 4. Other primary headaches 4.1 Primary stabbing headache 4.2 Primary cough headache 4.3 Primary exertional headache 4.4 Primary headache associated with sexual activity 4.5 Hypnic headache 4.6 Primary thunderclap headache 4.7 Hemicrania continua 4.8 New daily-persistent headache (NDPH) ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 68. 4.5 Hypnic headache New entrant to classification A. Dull headache fulfilling criteria B-D B. Develops only during sleep, and awakens patient C. At least two of the following characteristics: New entrant to classification 1. occurs >15 times/mo 2. lasts 15 min after waking 3. first occurs after age of 50 y D. No autonomic symptoms and no more than one of nausea, photophobia or phonophobia E. Not attributed to another disorder 4.5 Hypnic headache ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 69. 4.6 Primary thunderclap headache A. Severe head pain fulfilling criteria B and C B. Both of the following characteristics: 1. sudden onset, reaching maximum intensity in <1 min 2. lasting from 1 h to 10 d C. Does not recur regularly over subsequent weeks or months D. Not attributed to another disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 70. 4.7 Hemicrania continua New entrant to classification A. Headache for >3 mo fulfilling criteria B-D B. All of the following characteristics: 1. unilateral pain without side-shift 2. daily and continuous, without pain-free periods 3. moderate intensity, with exacerbations of severe pain C. At least one of the following autonomic features occurs during exacerbations, ipsilateral to the pain: 1. conjunctival injection and/or lacrimation 2. nasal congestion and/or rhinorrhoea 3. ptosis and/or miosis D. Complete response to therapeutic doses of indomethacin E. Not attributed to another disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 71. 4.8 New daily-persistent headache New entrant to classification A. Headache for >3 mo fulfilling criteria B-D B. Headache is daily and unremitting from onset or from <3 d from onset C. At least two of the following pain characteristics: New entrant to classification 1. bilateral location 2. pressing/tightening (non-pulsating) quality 3. mild or moderate intensity 4. not aggravated by routine physical activity D. Both of the following: 1. not >1 of photophobia, phonophobia or mild nausea 2. neither moderate or severe nausea nor vomiting E. Not attributed to another disorder 4.8 New daily-persistent headache ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 72. Primary Chronic Daily Headache Disorders of Long-Duration (>4 h) Disorder Demographic Clinical Features Recommended Treatments Chronic migraine Headache ≥15 days per month for >3 mo, of which ≥8 days Female/male, 3 : 1 Prevalence Topiramate, divalproex sodium, meet ICHD-II criteria for 2% amitriptyline migraine without aura or relief with triptan or ergot Mild-moderate severity; no Chronic tension-type headache Equal sex ratio Prevalence 2% migrainous symptoms; bilateral, Amitriptyline nonthrobbing New daily persistent headache Female > male Bilateral, persistent, moderately severe; may be preceded by viral infection; may resemble Amitriptyline migraine or tension-type headache Hemicrania continua Rare; unilateral, constant, exacerbations of severe headache, cranial autonomic Indomethacin symptoms, and ice-pick pain; responsive to indomethacin by definition Female > male
  • 73. Diagnostic criteria for secondary headaches A. Headache with one (or more) of the following [listed] characteristics and fulfilling criteria C and D B. Another disorder known to be able to cause headache has been demonstrated C. Headache occurs in close temporal relation to the other disorder and/or there is other evidence of a causal relationship D. Headache is greatly reduced or resolves within 3 mo (shorter for some disorders) after successful treatment or spontaneous remission of the causative disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 74. 6. Headache attributed to cranial or cervical vascular disorder 6.1 Headache attributed to ischaemic stroke or transient ischaemic attack 6.2 Headache attributed to non-traumatic intracranial haemorrhage 6.3 Headache attributed to unruptured vascular malformation 6.4 Headache attributed to arteritis 6.5 Carotid or vertebral artery pain 6.6 Headache attributed to cerebral venous thrombosis 6.7 Headache attributed to other intracranial vascular disorder ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 75. 6.4.1 Headache attributed to giant cell arteritis A. Any new persisting headache fulfilling criteria C and D B. At least one of the following: 1. swollen tender scalp artery with elevated erythrocyte sedimentation rate (ESR) and/or C reactive protein (CRP) 2. temporal artery biopsy demonstrating giant cell arteritis C. Headache develops in close temporal relation to other symptoms and signs of giant cell arteritis D. Headache resolves or greatly improves within 3 d of high-dose steroid treatment ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 76. 6.7.1 CADASIL A. Attacks of migraine with aura, with or without other neurological signs B. Typical white matter changes on MRI T2WI C. Diagnostic confirmation from skin biopsy evidence or genetic testing (Notch 3 mutations) ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 77. 7.4.2 Headache attributed directly to neoplasm A. Headache with 1 of the following characteristics and fulfilling criteria C and D: 1. progressive 2. localised 3. worse in the morning 4. aggravated by coughing or bending forward B. Intracranial neoplasm shown by imaging C. Headache develops in temporal (and usually spatial) relation to the neoplasm D. Headache resolves within 7 d after surgical removal or volume-reduction of neoplasm or treatment with corticosteroids ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 78. 9.1 Headache attributed to intracranial infection 9.1.1 Headache attributed to bacterial meningitis 9.1.2 Headache attributed to lymphocytic meningitis 9.1.3 Headache attributed to encephalitis 9.1.4 Headache attributed to brain abscess 9.1.5 Headache attributed to subdural empyema ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 79. 9.1.1 Headache attributed to bacterial meningitis A. Headache with 1 of the following characteristics and fulfilling criteria C and D: 1. diffuse pain 2. intensity increasing to severe 3. associated with nausea, photophobia and/or phonophobia B. Evidence of bacterial meningitis from examination of CSF C. Headache develops during the meningitis D. One or other of the following: 1. headache resolves within 3 mo after relief from meningitis 2. headache persists but 3 mo have not yet passed since relief from meningitis 9.1.1 Headache attributed to bacterial meningitis ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 80. 9.1.1 Headache attributed to bacterial meningitis Notes • Criterion D does not relate to evidence of causation • Causation is established by onset during diagnosed bacterial meningitis, whilst it is well recognised that this headache often persists • When this occurs, 9.4.1 Chronic post-bacterial meningitis headache is diagnosed • Criterion D2 allows a default diagnosis within 3 mo, before it is known whether headache will resolve or persist ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4
  • 81. 9.2 Headache attributed to systemic infection A. Headache with 1 of the following characteristics and fulfilling criteria C and D: 1. diffuse pain 2. intensity increasing to moderate or severe 3. associated with fever, general malaise or other symptoms of systemic infection B. Evidence of systemic infection C. Headache develops during the systemic infection D. Headache resolves within 72 h after effective treatment of the infection ICHD-II. Cephalalgia 2004; 24 (Suppl 1) ©International Headache Society 2003/4

Notas del editor

  1. NOT in Handout!!Similar choice for pt with rapid onset of migraine and with early n/v – need something non-oral or that works fastRecurrence = migraine initially gone, but comes back within 24 hours, something longer acting may outlast the migraine and keep it from coming back or addition of NSAID that lasts longer than triptanNara, Frova and Almo have lower rates of SE vs. other triptans and may be tolerated when other triptans were notNasal formulation available for sumatriptan, zolmitriptan, and DHEODT formulations available for rizatriptan and zolmitriptan
  2. NNT not in handout
  3. SJS = Steven’s Johnson SyndromeSuicidal behavior and AEDs – FDA pooled data of all RDBPCT trials of AEDs showed 0.43% of pt on AEDs vs. 0.24% of pt on placebo reported suicidal behavior, regardless of indication. Translates to 1 additional case of suicidal behavior/ideation per 530 pt. treated with AED. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm
  4. NNT not in handout
  5. Additional info not in handout
  6. Not in handout